• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Levetiracetam Dexcel 250, 500, 1000
    / Dexcel


    Active Ingredient
    Levetiracetam 250, 500, 750, 1000 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    60 X 250 mg

    partial basket chart 64802

    Tablets

    60 X 500 mg

    partial basket chart 64801

    Tablets

    60 X 1000 mg

    partial basket chart 64800

    Related information


    Dosage

    Monotherapy:
    Adults and adolescents from 16 years of age: 
    The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.
    Add-on therapy:
    Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: 
    The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks.
    Special population:
    Children aged 6 to 11 years and adolescents (12 to 17 years) weighing less than 50 kg: 
    The initial therapeutic dose is 10 mg/kg twice daily.
    Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used.
    See prescribing information for full details.


    Indications

    Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
    Levetiracetam is indicated as adjunctive therapy:
    – In the treatment of partial onset seizures with or without secondary generalisation in adults and children from 6 years of age with epilepsy.
    – In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
    – In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.


    Contra-Indications

    Hypersensitivity to levetiracetam or other pyrrolidone derivatives or any of the excipients.
    See prescribing information for full details.


    Manufacturer
    Dexcel Ltd.
    Licence holder
    CLOSE